Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Related Resources

Related Resources

University Hospital Jena: Study evaluated response rate and safety in patients with HCC treated with DEB-TACE using 40-µm microspheres

Researchers at the University Hospital Jena analyzed the response rate and safety of superselective drug-eluting beads transarterial chemoembolization…

University Hospital Tübingen: Study examined correlation between 18f-fdg PET and CT texture parameters in metastatic melanoma patients

An exploratory study [1] conducted by researchers at University Hospital Tuebingen investigated whether CT texture analysis parameters correlate with…

University Hospital Cologne: Study provides guidance values of iodine concentration for body CT examinations

Using data from a large cohort of individuals without radiological tumor burden, researchers from University Hospital Cologne have conducted a study…